Episode Details

Trigger Warning: cancer treatment, cancer and side effects.

Bonus Episode: Rad Chat Live at UKIO Conference 2025 with Maryam Akhtarini.

Stay ahead in radiotherapy and oncology by liking, following, and subscribing to Rad Chat wherever you get your podcasts.

Join our supportive community of professionals who truly get it. Follow us @Rad__Chat and visit our website at www.radchat.co.uk. Together, we’re pushing boundaries in cancer care.

Maryam’s links:
FDA Approval of Histotripsy for Liver Tumors (Oct 2023)
https://www.fda.gov/news-events/press-announcements/fda-roundup-october-13-2023
https://www.fusfoundation.org/posts/fda-approves-histotripsy-for-liver-tumors/

UK Early Market Access via IDAP (May 2025)
https://www.businesswire.com/news/home/20250529975697/en/HistoSonics-Edison-Histotripsy-System-Gains-Great-Britain-Early-Market-Access-Under-Unmet-Clinical-Needs-Authorisation

HOPE4LIVER Trial Results (April 2025)
https://www.businesswire.com/news/home/20250428931117/en/HistoSonics-Histotripsy-System-Demonstrates-90-Local-Tumor-Control-at-12-Months-in-HOPE4LIVER-Trials
https://www.fusfoundation.org/posts/histotripsy-for-liver-tumors-one-year-data-suggest-90-tumor-control/

Histotripsy Overview (Non-Thermal Ultrasound)
https://ammf.org.uk/2025/05/30/histotripsy-and-cholangiocarcinoma/

NanOx and Tumour Hypoxia – Cancer Letters (Dec 2024)
https://pubmed.ncbi.nlm.nih.gov/39716484/https://www.researchgate.net/publication/387307211_Enhancing_cancer_radiotherapy_efficacy_using_NanOx_a_novel_oxygenating_perfluorocarbon_nanoemulsion_that_reverses_tumour_hypoxia
https://www.sciencedirect.com/science/article/abs/pii/S0304383524008012

Rad Chat Links:

• Rad Chat Website
• Link Tree
• Facebook
• Instagram
• LinkedIn
• TikTok
• BlueSky
• YouTube

© Rad Chat 2025. All rights reserved.  

We (or our licensors) own all intellectual property rights in this podcast and all related content, online and offline.  

You may not use, copy, modify, download, archive, reproduce, distribute, display, publish, licence, create derivative works from or commercially exploit any part of our content unle